Biologic predictors of clinical improvement in rituximab-treated refractory myositis

IFN Priming Is Necessary but Not Sufficient To Turn on a Migratory Dendritic Cell Program in Lupus Monocytes

(2014) A. Rodriguez-Pla et al.   JOURNAL OF IMMUNOLOGY

Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature

(2013) Linda Nalotto et al.   IMMUNOLOGIC RESEARCH

Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies

(2013) I. N. Lazarou et al.   JOURNAL OF RHEUMATOLOGY

Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course

(2012) Ann M. Reed et al.   ARTHRITIS AND RHEUMATISM

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial

(2012) Chester V. Oddis et al.   ARTHRITIS AND RHEUMATISM

Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations

(2012) Floranne C. Ernste et al.   MAYO CLINIC PROCEEDINGS

Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis

(2011) Yasuhito Hamaguchi et al.   ARCHIVES OF DERMATOLOGY

Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand

(2010) P. Szodoray et al.   RHEUMATOLOGY

Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients

(2008) Qiong Fu et al.   ARTHRITIS RESEARCH & THERAPY